Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
复制标题
Pluronic p85增强了外膜囊泡作为亚基疫苗的疗效，以针对小鼠的布鲁氏菌Melitensis挑战。
DOI：
10.1111/1574-695x.12010
复制
发表时间：
2012-12
影响因子：
--
通讯作者：
Sriranganathan N
中科院分区：
文献类型：
--
作者：
Jain-Gupta N;Contreras-Rodriguez A;Vemulapalli R;Witonsky SG;Boyle SM;Sriranganathan N
布鲁氏菌病是世界范围内最常见的人畜共患疾病，目前尚无可供人类使用的疫苗。羊布鲁氏菌 Rev1 是一种减毒活菌株，是用于小型反刍动物的商业疫苗，用于预防羊布鲁氏菌感染，但与动物流产有关。此外，已知菌株 Rev1 会引起人类疾病，因此不能用于人类疫苗接种。从羊种伯克霍尔德氏菌中获得的外膜囊泡 (OMV) 已被证明可以提供类似于小鼠菌株 Rev1 的保护，以抵抗羊种伯克氏菌的攻击。在目前的工作中，我们测试了 Pluronic P85 作为佐剂的功效，以增强布鲁氏菌 OMV 作为疫苗的功效。 P85 增强 OMV 和 P85 诱导的巨噬细胞体外分泌 TNF-α。此外，P85 增强了 OMV 针对羊种芽孢杆菌攻击提供的保护。这种增强的保护与较高的总 IgG 抗体产生相关，但与 IFN-γ 或 IL-4 细胞因子水平的增加无关。此外，与接种盐水疫苗的小鼠相比，单独使用 P85 可以显着更好地清除羊种巴氏杆菌。需要进一步的研究来找到 P85 的作用机制，该机制提供非特异性保护并增强 OMV 作为羊种布鲁氏菌疫苗的功效。
Brucellosis is the most common zoonotic disease worldwide and there is no vaccine for human use. Brucella melitensis Rev1, a live attenuated strain, is the commercial vaccine for small ruminants to prevent B. melitensis infections but has been associated with abortions in animals. Moreover, strain Rev1 is known to cause disease in humans and cannot be used for human vaccination. Outer membrane vesicles (OMVs) obtained from B. melitensis have been shown to provide protection similar to strain Rev1 in mice against B. melitensis challenge. In the present work we tested the efficacy of Pluronic P85 as an adjuvant to enhance the efficacy of Brucella OMVs as a vaccine. P85 enhanced the in vitro secretion of TNF-α by macrophages induced with OMVs and P85. Further, P85 enhanced the protection provided by OMVs against B. melitensis challenge. This enhanced protection was associated with higher total IgG antibody production but not increased IFN-γ or IL-4 cytokine levels. Moreover, P85 alone provided significantly better clearance of B. melitensis compared to saline vaccinated mice. Further studies are warranted to find the mechanism of action of P85 that provides non-specific protection and enhances the efficacy of OMVs as a vaccine against B. melitensis.